라파스

214260KOSDAQ기타 화학제품 제조업

46.8 / 100

Reference Date: 2026-06-10

Financial Score11.5 / 40

News Sentiment21.3 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE is below the industry average, ROE is below the industry average. Plunged 17.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Raphas specializes in the research, development, manufacturing, and sales of patches using dissolvable microneedles technology. Leveraging its proprietary DEN technology, the company produces microneedles at room temperature without heat or UV exposure, enabling applications in sensitive bio-pharmaceuticals. Currently focused on the cosmetics market, Raphas plans to expand into pharmaceuticals, vaccines, and medical devices, with ongoing collaborations with Serum Institute and Boehringer Ingelheim for vaccine and therapeutic patch development.

Number of Employees

103people

Average Salary

49.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 16.504.0Point

PBR

2.18Industry Average 1.131.0Point

1.9x industry avg (risky)

ROE

-15.21Industry Average 4.550.0Point

Well below industry avg

Debt Ratio

10.91Industry Average 8.132.0Point

Higher than industry avg (caution)

Trend 2023~20254.5 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲5.6% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲13.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -19.2% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 5Neutral 0Negative 0Average Sentiment Score 85

Positive
라파스, 여드름 치료용 마이크로니들 패치 중동 시장 진출
라파스의 중동 시장 진출로 인해 아크네큐어의 글로벌 신뢰성이 향상되어 긍정적인 시장 반응 예상.
Positive
라파스, 중동 9개국 대상 ‘아크네큐어’ 공급 추진
라파스의 중동 시장 진출로 아크네큐어의 글로벌 확장 기대, 긍정적 영향 예상.
Positive
라파스, '붙이는 알레르기 치료제' 시대 연다… 마이크로니들 의약품.....
라파스의 마이크로니들 기반 알레르기 치료제 상용화 소식으로 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 7,500Won52-week high 17,87052-week low 6,790

1-month return0.0Point

1m -17.40% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-02
Neutral[기재정정]투자판단관련주요경영사항(임상시험계획승인신청) (알레르기비염 면역치료제 DF19001의 임상 2b/3상 임상시험계획(IND) 승인 신청)2026-05-28
Neutral투자판단관련주요경영사항(임상시험계획승인신청) (알레르기비염 면역치료제 DF19001의 임상 2b/3상 임상시험계획(IND) 승인 신청)2026-05-22
Neutral분기보고서 (2026.03)2026-05-15
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-12